FDA Approves Isatuximab-irfc for Previously Treated Myeloma
March 3rd 2020The Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa) plus pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who had 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.